EC Number   |
Protein Variants |
Reference |
|---|
   3.4.19.6 | C279S |
specific activity is 10fold lower than that of the wild-type enzyme |
647287 |
| 3.4.19.6 | C338S |
specific activity is 5fold lower than that of the wild-type enzyme |
647287 |
| 3.4.19.6 | C68S |
specific enzymatic activities are similar to that of the wild-type enzyme |
647287 |
| 3.4.19.6 | C823S |
mutant enzyme is completely inactive |
647287 |
| 3.4.19.6 | C830S |
mutant enzyme is completely inactive |
647287 |
| 3.4.19.6 | C859S |
mutant enzyme is completely inactive |
647287 |
| 3.4.19.6 | K463N |
mutant losses omega-peptidase but displays alanyl-aminopeptidase activity |
669472 |
| 3.4.19.6 | more |
detection of a RNA species derived from an alternative processing at the exon 14intron 14 boundary. The alternatively processed RNA encodes a shorter version of PPII (PPII*), lacking part of the C-terminal domain. PPII* is expressed in COS-7 (or C6 glioma) cells but it does not exhibit any PPII activity. Co-transfection of PPII and increasing amounts of PPII* expression vectors results in a dose-dependent reduction in PPII activity and the formation of covalent PPIIPPII* heterodimers. PPII* is therefore a powerful dominant-negative isoform of PPII, and heterodimerization may be its mechanism of action. Natural expression of shortened versions of M1 aminopeptidases may constitute a new mode of regulation of their activity |
669931 |
| 3.4.19.6 | S269A |
mutant shows a 40% decrease in activity with thyrotropin-releasing hormone-beta-naphthylamide as substrate |
669472 |
| 3.4.19.6 | S269E |
mutant is inactive with thyrotropin-releasing hormone-beta-naphthylamide as substrate |
669472 |
